Definition
Premature Ventricular Contractions (PVCs) are single, isolated cardiac contractions originating from the ventricles. They intersperse transiently and potentially recurrently within the normal sinus rhythm. PVCs momentarily interrupt the physiologic rhythm, typically inducing a brief compensatory pause prior to the subsequent sinus contraction.
- Ventricular Bigeminy: A recurring pattern where an ectopic premature contraction follows every normal sinus beat.
- Ventricular Trigeminy: A recurring pattern where a premature contraction occurs after every two consecutive normal sinus beats.
- Ventricular Couplet: Two consecutive PVCs occurring in immediate succession.
- Non-Sustained Ventricular Tachycardia (NSVT): A run of three or more consecutive ventricular beats with a rate exceeding 100 beats per minute.
PVCs represent a highly prevalent clinical phenomenon. Patients frequently perceive them as brief pauses or forceful palpitations, often described as a "fluttering" or "thumping" sensation in the chest.
Etiology
PVCs can be precipitated by a broad spectrum of cardiovascular and non-cardiovascular etiologies.
Cardiovascular Etiologies:
- Acute myocardial infarction or myocardial ischemia.
- Myocarditis.
- Ischemic, dilated, or hypertrophic cardiomyopathy.
- Valvular heart disease.
Non-Cardiovascular Etiologies:
- Hypoxia and hypercapnia.
- Pharmacological agents (e.g., digoxin, sympathomimetics, tricyclic antidepressants, aminophylline, caffeine).
- Substances of abuse (e.g., cocaine, amphetamines, alcohol, tobacco).
- Electrolyte disturbances (e.g., hypomagnesemia, hypokalemia, hypercalcemia).
Frequently, PVCs manifest in the absolute absence of an underlying pathological substrate, as confirmed by comprehensive clinical and paraclinical diagnostic evaluation.
Symptomatology
- Palpitations: PVCs are often felt as brief cardiac pauses or "thumping" sensations. Because the contraction is premature, ventricular filling time is shortened, resulting in a reduced stroke volume during the ectopic beat. Consequently, the end-diastolic volume increases prior to the next normal sinus beat, producing a highly forceful and palpable contraction.
- Hemodynamic Presentation: In ventricular bigeminy, the reduced stroke volume of the premature beat can fail to generate a palpable peripheral pulse (ineffective contraction). This presentation mimics bradycardia, potentially causing weakness and fatigue. Automated electronic sphygmomanometers may falsely register the pulse rate at half its true value (e.g., 30 bpm instead of 60 bpm).
- Asymptomatic Burden: PVCs may remain completely asymptomatic. However, a high daily arrhythmic burden (>10,000 PVCs per 24 hours) can induce ventricular dyssynchrony, leading to myocardial dysfunction and symptoms of heart failure, such as a reduced ejection fraction.
Clinical Significance
In individuals without structural heart disease, PVCs are typically benign, do not imply an adverse prognosis, and require no therapeutic intervention if asymptomatic. The primary exception involves a high arrhythmic burden (>10,000 PVCs per 24 hours), which can cause tachycardiomyopathy and secondary heart failure.
Conversely, PVCs in patients with structural heart disease warrant meticulous evaluation, as they may signal a deterioration of global cardiac function requiring targeted etiological treatment. In patients with a history of myocardial infarction and a reduced ejection fraction (<40%), a high PVC burden indicates an elevated risk for sudden cardiac death (SCD) and may necessitate further invasive risk stratification via an electrophysiological study (EPS).
Diagnostic Evaluation
PVCs are definitively diagnosed via a standard 12-lead electrocardiogram (ECG) or continuous 24-hour Holter monitoring. When structural heart disease is clinically suspected, an extended diagnostic workup is required.
Management
Therapeutic management depends on symptom severity and the presence or absence of underlying structural heart disease.
PVCs in the Absence of Structural Heart Disease:
- Asymptomatic Patients: No treatment is indicated unless the arrhythmic burden exceeds the threshold of 10,000 PVCs per 24 hours.
- Symptomatic or High-Burden Patients: Intervention aims to minimize the arrhythmic burden and alleviate symptoms using pharmacotherapy (beta-blockers, sotalol, or amiodarone). In patients with a structurally normal heart, catheter ablation constitutes the definitive therapy of choice.
PVCs in the Presence of Structural Heart Disease:
- Asymptomatic Patients: Targeted suppression of PVCs is not indicated. Management focuses strictly on optimized guideline-directed medical therapy for the primary cardiovascular disease.
- Symptomatic Patients: Along with treating the underlying heart disease and correcting exacerbating factors (e.g., electrolyte imbalances, renal insufficiency), medical suppression can be initiated with beta-blockers or amiodarone. Other antiarrhythmic drugs (such as propafenone, flecainide, and sotalol) must be avoided due to their proarrhythmic risk and potential to worsen the primary cardiac pathology, with a potential exception made for mexiletine. If pharmacotherapy fails, and symptoms or cardiac dysfunction remain severe, catheter ablation should be considered.